Completed PHASE3 INTERVENTIONAL 2-arm NCT00105443

A Phase III Study of Sorafenib in Patients With Advanced Hepatocellular Carcinoma (SHARP)

A Phase III Randomized, Placebo-controlled Study of Sorafenib in Patients With Advanced Hepatocellular Carcinoma

Sponsor: Bayer

Interventions Placebo Sorafenib (Nexavar, BAY43-9006)

Updated 7 times since 2017 Last updated: Oct 24, 2014 Started: Mar 31, 2005 Primary completion: Nov 30, 2008 Completion: Nov 30, 2008

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT00105443, this PHASE3 trial focuses on Carcinoma, Hepatocellular and remains completed. Sponsored by Bayer, it has been updated 7 times since 2005, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Status Flow

Change History

7 versions recorded

Sep 2025 — Present [monthly]

Completed PHASE3
Sep 2024 — Sep 2025 [monthly]

Completed PHASE3
Jul 2024 — Sep 2024 [monthly]

Completed PHASE3
Jan 2021 — Jul 2024 [monthly]

Completed PHASE3
Jun 2018 — Jan 2021 [monthly]

Completed PHASE3

▶ Show 2 earlier versions

Feb 2017 — Jun 2018 [monthly]

Completed PHASE3
Jan 2017 — Feb 2017 [monthly]

Completed PHASE3

First recorded

Mar 2005

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Bayer

Data source: Bayer

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Alicante, Spain , Ann Arbor, United States , Athens, Greece , Atlanta, United States , Auckland, New Zealand , Avellino, Italy , Badalona, Spain , Barcelona, Spain , Belo Horizonte, Brazil , Berlin, Germany and 130 more locations